Evommune (EVMN) Revenue (2025)
Evommune's (EVMN) quarterly Revenue came in at $10.0 million in Q3 2025, up 233.33% on a QoQ basis from $3.0 million in Q1 2025.
Evommune (EVMN) Revenue (2025) Analysis & Trends
Evommune (EVMN) has 1 years of Revenue data on file, last reported at $10.0 million in Q3 2025.
- On a quarterly basis, Revenue changed N/A year-over-year to $10.0 million in Q3 2025; TTM through Mar 2026 was $13.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $13.0 million, up 85.71% from the prior year.
- Revenue for Q3 2025 stood at $10.0 million, up from $3.0 million in the prior quarter.
- Over the last five years, Revenue for EVMN reached as high as $10.0 million in Q3 2025 and fell as low as $3.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Evommune | 380.30 Mn | 168.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 10.00 Mn |
| Mar 31, 2025 | 3.00 Mn |